Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study

CONCLUSIONS: Pegsitacianine was well tolerated and facilitated the recognition of occult residual disease following CRS. The high rate of residual disease detected suggests that the use of pegsitacianine augmented surgeon assessment and performance during CRS.PMID:38622456 | DOI:10.1245/s10434-024-15165-4

Source: Ann Oncol - April 15, 2024 Category: Cancer & Oncology Authors: Patrick Wagner Edward A Levine Alex C Kim Perry Shen Nicole D Fleming Shannon N Westin Laurel K Berry Giorgos C Karakousis Janos L Tanyi Madeline T Olson Brian Madajewski Brian Ostrander Kartik Krishnan Charles M Balch David L Bartlett Source Type: research